Full Title
Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma (AMC-112) (CIRB)Purpose
This study is assessing axicabtagene clioleucel CAR T cell therapy for people with HIV-related aggressive B cell lymphoma. The people in this study have B cell non-Hodgkin lymphoma that has come back or keeps growing after treatment, including:
- Diffuse large B cell lymphoma
- High-grade B cell lymphoma
- Primary mediastinal B cell lymphoma
- Follicular lymphoma grade 3B
T cells are immune cells that can kill tumor cells. Axicabtagene ciloleucel is made of genetically modified T cells that were altered in a lab to recognize CD19. The CD19 protein is on the surface of B cell cancer cells.
Axicabtagene ciloleucel is given once intravenously (by vein). You will also get cyclophosphamide and fludarabine to prepare your body for the CAR T cell therapy.
Who Can Join
To join this study, there are a few conditions. You must:
- Have HIV-related B cell lymphoma that is growing within 12 months of your last treatment OR has come back after at least 2 prior regimens of lymphoma therapy.
- Have a viral load of HIV below 50 copies/mL within 6 months of registering for the study.
- Have recovered from the serious side effects of previous lymphoma treatments.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. M. Lia Palomba’s office at 646-608-3711.